Diagnostic Imaging Devices are used for the visualization of structural and functional patterns of organs or tissues. Contrast Agents include Computed Tomography (CT) Contrast Agents, Magnetic Resonance Imaging (MRI) Contrast Agents, and Ultrasound Contrast Agents (microbubbles). GlobalData uses proprietary data and analytics to provide a comprehensive report on the contrast agents market in Italy. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the contrast agents market in Italy was Bracco Imaging followed by Bayer, GE HealthCare Technologies, Guerbet and Lantheus Medical Imaging.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
CT Contrast Agents are used for patients at high risk of colon cancer, for full-motion heart scans in those with a high risk of heart disease, and to image complex fractures. They can also detect infarctions, tumors, calcifications, hemorrhages, bone trauma, and acute or chronic changes in the lung parenchyma. This category includes Ionic Iodinated CT Contrast Agents, Non-ionic Iodinated CT Contrast Agents, and Barium CT Contrast Agents. MRI Contrast Agents utilize radiofrequency and a strong magnetic field to generate clear and detailed images of internal organs and tissues. They enhance the clarity of MRI images by affecting the relaxation rates of water molecules in the tissue. Ultrasound Contrast Agents (microbubbles) act as acoustic backscatterers, improving image quality through the use of various operational modes
The contrast agents market in Italy can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size contrast agents in Italy, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
